These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2471558)

  • 1. Isolation and characterization of the factor X Friuli variant.
    Fair DS; Revak DJ; Hubbard JG; Girolami A
    Blood; 1989 Jun; 73(8):2108-16. PubMed ID: 2471558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The preparation of activated factor X and its action on prothrombin.
    Jesty J; Esnouf MP
    Biochem J; 1973 Apr; 131(4):791-9. PubMed ID: 4737325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").
    Watzke HH; Lechner K; Roberts HR; Reddy SV; Welsch DJ; Friedman P; Mahr G; Jagadeeswaran P; Monroe DM; High KA
    J Biol Chem; 1990 Jul; 265(20):11982-9. PubMed ID: 1973167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction, expression, and characterization of a chimera of factor IX and factor X. The role of the second epidermal growth factor domain and serine protease domain in factor Va binding.
    Hertzberg MS; Ben-Tal O; Furie B; Furie BC
    J Biol Chem; 1992 Jul; 267(21):14759-66. PubMed ID: 1634519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex.
    Baugh RJ; Krishnaswamy S
    J Biol Chem; 1996 Jul; 271(27):16126-34. PubMed ID: 8663201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor X Friuli Coagulation Disorder: Almost 50 Years Later.
    Girolami A; Cosi E; Santarossa C; Ferrari S; Girolami B; Lombardi AM
    Clin Appl Thromb Hemost; 2018 Jan; 24(1):33-40. PubMed ID: 28030967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor X assays using chromogenic substrate S-2222.
    Girolami A; Saggin L; Boeri G
    Am J Clin Pathol; 1980 Mar; 73(3):400-2. PubMed ID: 7361721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of the high molecular form of bovine factor X and some of its physical properties.
    Yue RH; Gertler MM
    Biochim Biophys Acta; 1977 Feb; 490(2):350-62. PubMed ID: 836878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional consequences of the Ser334-->Pro mutation in a human factor X variant (factor XMarseille).
    Bezeaud A; Miyata T; Helley D; Zeng YZ; Kato H; Aillaud MF; Juhan-Vague I; Guillin MC
    Eur J Biochem; 1995 Nov; 234(1):140-7. PubMed ID: 8529633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor X activating enzyme from Russell's viper venom: isolation and characterization.
    Kisiel W; Hermodson MA; Davie EW
    Biochemistry; 1976 Nov; 15(22):4901-6. PubMed ID: 990251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degradation of coagulation proteins by an enzyme from Malayan pit viper (Akistrodon rhodostoma) venom.
    Lollar P; Parker CG; Kajenski PJ; Litwiller RD; Fass DN
    Biochemistry; 1987 Dec; 26(24):7627-36. PubMed ID: 3322404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
    Fair DS; Edgington TS
    Br J Haematol; 1985 Feb; 59(2):235-48. PubMed ID: 3970856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and characterization of mouse coagulation factor X -- biophysical and enzymological properties.
    James HL; Larson PJ; Chao YB; Yan SB; Kim DJ
    Thromb Haemost; 1997 Sep; 78(3):1049-54. PubMed ID: 9308752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A family with heterozygous factor X Friuli defect outside Friuli.
    Girolami A; Lazzarin M; Procidano M; Luzzatto G
    Blut; 1983 Mar; 46(3):149-54. PubMed ID: 6824795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular recognition in the activation of human blood coagulation factor X.
    Chattopadhyay A; Fair DS
    J Biol Chem; 1989 Jul; 264(19):11035-43. PubMed ID: 2500433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a homozygous Gly11Val mutation in the Gla domain of coagulation factor X.
    Chafa O; Tagzirt M; Tapon-Bretaudière J; Reghis A; Fischer AM; LeBonniec BF
    Thromb Res; 2009 May; 124(1):144-8. PubMed ID: 19135706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid purification of factor IX, factor X and prothrombin by immunoaffinity and ion exchange chromatography.
    Ahmad SS; Rawala-Sheikh R; Thompson AR; Walsh PN
    Thromb Res; 1989 Jul; 55(1):121-33. PubMed ID: 2781515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of bovine factor V by an activator purified from the venom of Naja naja oxiana.
    Gerads I; Tans G; Yukelson LYa ; Zwaal RF; Rosing J
    Toxicon; 1992 Sep; 30(9):1065-79. PubMed ID: 1440644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of factor X activity by factor X-specific monoclonal antibodies.
    Ouellette LA; Messier TL; Church WR
    Blood Coagul Fibrinolysis; 1992 Oct; 3(5):563-74. PubMed ID: 1450323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional properties of human factor Va lacking the Asp683-Arg709 domain of the heavy chain.
    Bakker HM; Tans G; Thomassen MC; Yukelson LY; Ebberink R; Hemker HC; Rosing J
    J Biol Chem; 1994 Aug; 269(32):20662-7. PubMed ID: 8051166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.